
Current Business Areas

Agro & Life Solutions AGL



ROIC※1
5.7%
(+1.3 pts YoY)

Core Operating Income※2
¥56.3 billion
(+¥1.4 billion YoY)

※1 Data up to FY2023 represents Health & Crop Sciences Sector
※2 Data up to FY2022 represents Health & Crop Sciences Sector

KEY POINT

AgroSolution (Chemicals, Biorationals)
- **World-leading drug development capabilities**
- **Footprint covering world major markets**

AgroSolutions Business (Chemicals, Biorationals)
Environmental Health Business (Chemicals・Biorational insecticides)
Animal Nutrition Business (Methionine)




◀ Chemical crop protection sold worldwide (from left, INDIFLIN™ and Rapidicil™)



▶ Biorationals such as microorganism-based crop protection and plant growth regulators (ABSUP™)

NEWS & TOPICS
- Established Sumitomo Biorational Company, a new integrated company for biorationals (April 2026)
- Rapidicil™ received registration as a chemical crop protection product in the U.S. (July 2026)

ICT & Mobility Solutions ICTM



ROIC※3
6.4%
(-4.0 pts YoY)

Core Operating Income※4
¥53.0 billion
(-¥17.5 billion YoY)


※3 Data up to FY2023 represents IT-related Chemicals Sector and Energy & Functional Materials Sector
※4 Data up to FY2022 represents IT-related Chemicals Sector and Energy & Functional Materials Secto

KEY POINT
- Photoresists **World-leading technological expertise**
- Semiconductor chemicals **World-leading high quality and business scale**
- Polarizers for OLED **No. 1 market share for mobile applications**

Semiconductor materials-related Business
(Photoresists, Semiconductor chemicals, Compound semiconductor materials, etc.)
Display Materials-related Business
(Polarizing films, Color Resists, etc.)
Mobility-related Business
(Super engineering plastics, Resorcinol, Battery separators, etc.)




◀ Photoresists, which are photosensitive resins used in the process of creating circuit patterns for semiconductor devices (SUMIRESIST™)



▶ Polarizers that reduce reflections on displays and contribute to ensuring visibility (SUMIKARAN™)

NEWS & TOPICS
- Acquired Asia Union Electronic Chemical Corporation (AUECC), a Taiwanese semiconductor process chemicals company. (January 2026)
- Signed a joint venture agreement with Samsung Electro-Mechanics Co., Ltd. on the glass core substrate business for advanced semiconductor packages (July 2026)

Advanced Medical Solutions ADM



ROIC
-0.7%
(+4.6 pts YoY)

Core Operating Income
¥2.8 billion
(-¥1.1 billion YoY)

KEY POINT
- Advanced small molecule APIs CDMO **No. 1 position in Japan**
- Oligonucleotide CDMO **Industry-leading quality capabilities**
- **A global leader in regenerative medicine/cell therapy fields** using iPS cells

CDMO business
(Advanced small molecule APIs, Oligonucleotide, Regenerative medicine/cell therapy)
Regenerative Medicine/Cell Therapy Business (R&D)




◀ Advanced small molecule APIs CDMO plant at Oita Works



▶ Regenerative medicine/cell therapy products (AMCHEPRY)

NEWS & TOPICS
- S-RACMO's regenerative medicine/cell therapy manufacturing facility, "CRAFT," was completed (July 2025)
- Obtained manufacturing and marketing approval for AMCHEPRY under the conditional and time-limited approval system (March 2026)

Essential & Green Materials EGM




ROIC※5
-7.7%
(+7.4 pts YoY)

Core Operating Income※6
¥14.4 billion
(+¥72.9 billion YoY)

※5 Data up to FY2023 represents Essential Chemicals & Plastics Sector
※6 Data up to FY2022 represents Essential Chemicals & Plastics Sector

KEY POINT
- Catalyst and Process Technology Licenses Approx. **70**
- We possess technologies enabling **the production of low environmental impact chemicals**
(e.g., PO-only Process, Hydrogen Chloride Oxidation Process)

Polyolefin Business (Polyethylene (PE), Polypropylene (PP))
Methyl Methacrylate (MMA) Business
Licensing Business




◀ Features of HCl Oxidation technology
Significantly reduces energy consumption and enables circular use of byproducts as raw materials. Reduces GHG emissions by 90% or more compared to the salt electrolysis technology.



▶ Demonstration facility for PMMA chemical recycling that efficiently pyrolyze acrylic resin using pyrolysis and regenerate it as MMA monomer, which is used as a raw material for acrylic resin (February 2026)


NEWS & TOPICS
- In collaboration with Lumas (U.S.), completed the development of commercial-scale technology for PMMA chemical recycling and began licensing it. (February 2026)
- In May 2026, our collaboration partner Technip (U.S.) entered into a global licensing agreement with BASF (Germany) for HCl Oxidation technology (May 2026)

Sales Revenue Composition Ratio




Key Performance Indicator


Core Operating Income




ROE・ROIC



Dividend Payout Ratio・Cash Dividends per Share




Interest-bearing Liabilities・D/E Ratio



Others

- **Sumitomo Pharma**
  - Small molecule drugs (R&D)
  - Regenerative medicine/cell therapy (R&D)



- **Others**
  - Utility supply of electric power and steam, transportation and warehousing services